Overview
Also known as:
Clinical phenotype terms— hover any for plain English:
FDA & Trial Timeline
10 eventsChina Immunotech (Beijing) Biotechnology Co., Ltd. — PHASE1
Peking Union Medical College Hospital — PHASE2
Centre Hospitalier Universitaire de Nice — NA
Yihao Wang — PHASE1, PHASE2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — PHASE1
Bing Han — PHASE2
Peking Union Medical College Hospital
Institute of Hematology & Blood Diseases Hospital, China — PHASE2
National Cancer Institute (NCI)
Zhejiang University — EARLY_PHASE1
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
3 availableAzacitidine
indicated for treatment of adult patients with refractory anemia (RA)
Azacitidine
indicated for the treatment of adult patients with refractory anemia (RA)
Reblozyl
REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate…
REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS)
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
1 resourcesTravel Grants
No travel grants are currently matched to Myelodysplastic neoplasm with low blasts.
Community
No community posts yet. Be the first to share your experience with Myelodysplastic neoplasm with low blasts.
Start the conversation →Latest news about Myelodysplastic neoplasm with low blasts
Disease timeline:
New recruiting trial: Quality of Life-Guided Transfusion in Refractory MDS or AML
A new clinical trial is recruiting patients for Myelodysplastic neoplasm with low blasts
New recruiting trial: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD
A new clinical trial is recruiting patients for Myelodysplastic neoplasm with low blasts
New trial: A Study of Avutometinib for People With Solid Tumor Cancers
Phase PHASE1 trial recruiting. Avutometinib
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Myelodysplastic neoplasm with low blasts
Are there clinical trials for Myelodysplastic neoplasm with low blasts?
Yes — 7 recruiting clinical trials are currently listed for Myelodysplastic neoplasm with low blasts on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Myelodysplastic neoplasm with low blasts?
25 specialists and care centers treating Myelodysplastic neoplasm with low blasts are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.